biotech
biotech Articles
Nabriva Therapeutics watched its shares take a step back on Monday's despite seeing positive results in its late-stage pneumonia trial.
Published:
Last Updated:
This year marks the 54th annual meeting of the American Society of Clinical Oncology, the world’s largest clinical cancer conference.
Published:
Last Updated:
Jounce Therapeutics watched its shares crumble on Thursday after the firm released data from its midstage cancer trial.
Published:
Last Updated:
Evolus watched its shares come crashing down on Wednesday after the company announced that the FDA issued a Complete Response Letter for its treatment of glabellar lines, also known as frown lines,...
Published:
Last Updated:
Abaxis shares hit an all-time high early on Wednesday after it was announced that Zoetis would be acquiring the firm.
Published:
Last Updated:
The April 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in May.
Published:
Last Updated:
Portola Pharmaceuticals saw its shares soar on Friday after the firm announced that it had received an approval from the FDA.
Published:
Last Updated:
As we have said before, the FDA has the potential to make or break biopharma companies, and in this case Achaogen is feeling the burn.
Published:
Last Updated:
InVivo Therapeutics shares absolutely skyrocketed on Wednesday after the firm provided an update on results from the company’s single-arm INSPIRE study.
Published:
Last Updated:
Gilead Science was supposed to be coming back as a company on the heels of its first major acquisition in years. Unfortunately, the post-earnings reaction has not been any help on that front.
Published:
Last Updated:
Esperion Therapeutics released its first-quarter financial results and a business update before the markets opened on Wednesday.
Published:
Last Updated:
Gilead Sciences released disappointing first-quarter financial results late Tuesday and shares tumbled early Wednesday.
Published:
Last Updated:
Karyopharm Therapeutics saw its shares make a handy gain on Tuesday after the firm announced positive top-line results from the Phase 2b STORM study evaluating selinexor.
Published:
Last Updated:
Regeneron Pharmaceuticals and Sanofi are committing to lowering the price of the anti-cholesterol drug Praluent.
Published:
Last Updated: